


塑造益生菌、活体生物药和粪菌移植的未来: 来自中国肠道大会的30条科学建议

汪韦宏、步楠、曹海龙、陈宁、陈卫、承磊、崔伯塔、戴磊、高慧英、郭梦、何兴祥、 胡佳、姜长涛、蒋先芝、李景南、李平、李伟、廖伟伟、刘宏伟、柳婧美、刘苓、 刘双江、刘星吟、吕沐翰、马永慧、满朝新、皮哲舜、任茜、桑力轩、孙志宏、索化夷、 谭验、陶万银、王光强、王军、王良静、王欣、王新、王晔、吴开春、乌日娜、吴振、 肖香、向斌、杨松、易华西、余汉濠、于君、曾悦、翟惠虹、翟齐啸、张晨虹、张国华、 张家超、张文羿、赵方庆、赵亮、周宏伟、朱莉、蓝灿辉、张和平、朱书、张发明



主要单位:宁波热心肠科技传播研究中心、内蒙古农业大学、中国科学技术大学、南京医科大学第二附属医院

Weihong Wang, Nan Bu, Hailong Cao, Ning Chen, Wei Chen, Lei Cheng, Bota Cui, et al. 2025. Shaping the future of probiotics, live biotherapeutic products, and fecal microbiota transplantation: 30 scientific recommendations from the CHINAGUT Conference. *iMeta* 4: e70083. https://doi.org/10.1002/imt2.70083

背景介绍


30 Scientific Recommendations on Microbiota-Based Treatments from the 2025 CHINAGUT Conference



Nicrobiota-Based Treatmont

WHY MAKE RECOMMENDATIONS?





- · The evidence of strainlevel deficiency
- Inconsistent therapeutic outcomes





- · Barriers in bench-tobedside translation
- · Unclear mechanism



- Confusion in clinical application
- Insufficient regulatory frameworks







Translation

Establish scientific benchmarks at the interaction

Conduct dosage and ratio verification

strain level

Clarify the mechanism of strain-host

Supported by highlevel clinical RCT research evidence

Supervision


RECOMMENDATIONS ON FIVE CORE POINTS

A panel of 63 experts (30 scientists, 26 physicians, and 7 corporate R&D personnel) collaborated in three groups, each contributing 10 recommendations, culminating in 30 scientific recommendations

> Construct a global regulatory pathway Eliminate misleading

dissemination and establish a credibility system

2025 CHINAGUT Conference



Whole-process

Improve the long-

traceability system

quality control

monitoring and

term safety

Regulation

Communication

Multi-subject collaboration in industry-academiaresearch-education based on microbiota medicine



WHAT ARE THE HIGHLIGHTS?

These scientific recommendations synthesize cutting-edge knowledge from multidisciplinary experts to establish practical guidelines for advancing microbiota-based treatments




Ten Scientific Recommendations for Promoting High-Quality Development of Probiotic Science and Industry

- High-quality Randomized controlled trials to verify health benefits
- Rigorous design with transparent reporting

- Clear labeling to prevent misleading claims
- Compliance with international and national regulations


- Foster innovation through industry and academia partnerships
- Science-based public and professional education



- Genome sequencing for strain identification, international deposition and nomenclature
 - Ensure reproducibility and product safety

- Evaluate synergistic or antagonistic effects to determine optimal ratios
- Dose determination based on clinical data, balancing cost-effectiveness
- Screen for antibiotic resistance genes, with focus on vulnerable populations
- Full lifecycle quality control, optimized production processes

第二部分 活体生物药产业发展的十条科学建议





第三部分 促进粪菌移植转化与可持续发展的十条科学建议

Ten Scientific Recommendations for Translational and Sustainable Development of Fecal Microbiota Transplantation

Regulation



- A National Regulatory Framework
- Nonprofit Medical Service Models
- High-Quality Public
 Fecal Microbiota Banks

Clinical Practice



- Evidence-Based Application
- Full-Process
 Standardization
- Robust Long-Term
 Follow-Up Systems

Research



- Public and Private Investment
- Multi-Stakeholder Collaboration
- Stringent Ethical Principles

Education





- Incorporation into General Medical Education
- Responsible Science Popularization

iMeta: To be top journals in biology and medicine

WILEY











"iMeta" launched in 2022 by iMeta Science Society, impact factor (IF) 33.2, ranking top 65/22249 in world and 2/161 in the microbiology. It aims to publish innovative and high-quality papers with broad and diverse audiences. Its scope is similar to Cell, Nature Biotechnology/Methods/Microbiology/Medicine/Food. Its unique features include video abstract, bilingual publication, and social media with 600,000 followers. Indexed by SCIE/ESI, PubMed, Google Scholar etc.

"iMetaOmics" launched in 2024, with a target IF>10, and its scope is similar to Nature Communications, Cell Reports, Microbiome, ISME J, Nucleic Acids Research, Briefings in Bioinformatics, etc.

"iMetaMed" launched in 2025, with a target IF>15, similar to Med, Cell Reports Medicine, eBioMedicine, eClinicalMedicine etc.

Society: http://www.imeta.science

Publisher: https://wileyonlinelibrary.com/journal/imeta

iMeta: https://wiley.atyponrex.com/journal/IMT2

Submission: iMetaOmics: https://wiley.atyponrex.com/journal/IMO2

iMetaMed: https://wiley.atyponrex.com/journal/IMM3

iMetaScience







Update 2025/7/6

Promotion Video